PubMedHealth treatment related to Melanoma: 59
After melanoma is diagnosed, the first step is usually to try to remove it surgically. If it is already advanced or metastatic tumors have developed elsewhere, surgery is combined with other treatments such as medication or radiation.
FDA approved drugs:
(show all 11)
| # |
|
Drug Name |
Active Ingredient(s) 17
|
Company |
Approval Date |
| 1 |
|
Erivedge
17
45
|
VISMODEGIB |
Genentech |
January 2012 |
Disease/s that Drug Treats:basal cell carcinoma
Indications and Usage:
17
ERIVEDGE (vismodegib) capsule is a hedgehog pathway inhibitor indicatedfor the treatment of adults with metastatic basal cell carcinoma, or with locallyadvanced basal cell carcinoma that has recurred following surgery or who arenot candidates for surgery, and who are not candidates for radiation. (1)
DrugBank Targets:
15
1. Smoothened homolog
Mechanism of Action:
17
Target: hedgehog (Hh) signaling pathway
Action: innhibitor
FDA: Vismodegib is an inhibitor of the Hedgehog pathway. Vismodegib binds to and inhibitsSmoothened, a transmembrane protein involved in Hedgehog signal transduction.
|
| 2 |
|
Intron A
17
45
|
INTERFERON ALFA-2B |
Schering-Plough |
December 1997/ December 1995/ March 1997 |
Disease/s that Drug Treats:non-Hodgkin's lymphoma/ malignant melanoma / Hepatitis C
Indications and Usage:
17
Hairy Cell Leukemia INTRON® A is indicated for the treatment of patients 18 years ofage or older with hairy cell leukemia.Malignant Melanoma INTRON A is indicated as adjuvant to surgical treatment inpatients 18 years of age or older with malignant melanoma who are free of disease butat high risk for systemic recurrence, within 56 days of surgery.Follicular Lymphoma INTRON A is indicated for the initial treatment of clinicallyaggressive (see Clinical Pharmacology) follicular Non-Hodgkinâs Lymphoma inconjunction with anthracycline-containing combination chemotherapy in patients 18years of age or older. Efficacy of INTRON A therapy in patients with low-grade, lowtumorburden follicular Non-Hodgkinâs Lymphoma has not been demonstrated.Condylomata Acuminata INTRON A is indicated for intralesional treatment of selectedpatients 18 years of age or older with condylomata acuminata involving externalsurfaces of the genital and perianal areas (see DOSAGE AND ADMINISTRATION).The use of this product in adolescents has not been studied.AIDS-Related Kaposi's Sarcoma INTRON A is indicated for the treatment of selectedpatients 18 years of age or older with AIDS-Related Kaposi's Sarcoma. The likelihoodof response to INTRON A therapy is greater in patients who are without systemic symptoms, who have limited lymphadenopathy and who have a relatively intact immunesystem as indicated by total CD4 count.Chronic Hepatitis C INTRON A is indicated for the treatment of chronic hepatitis C inpatients 18 years of age or older with compensated liver disease who have a history ofblood or blood-product exposure and/or are HCV antibody positive. Studies in thesepatients demonstrated that INTRON A therapy can produce clinically meaningful effectson this disease, manifested by normalization of serum alanine aminotransferase (ALT)and reduction in liver necrosis and degeneration.A liver biopsy should be performed to establish the diagnosis of chronic hepatitis.Patients should be tested for the presence of antibody to HCV. Patients with othercauses of chronic hepatitis, including autoimmune hepatitis, should be excluded. Priorto initiation of INTRON A therapy, the physician should establish that the patient hascompensated liver disease. The following patient entrance criteria for compensated liverdisease were used in the clinical studies and should be considered before INTRON Atreatment of patients with chronic hepatitis C: No history of hepatic encephalopathy, variceal bleeding, ascites, or otherclinical signs of decompensation Bilirubin Less than or equal to 2 mg/dL Albumin Stable and within normal limits Prothrombin Time Less than 3 seconds prolonged WBC Greater than or equal to 3000/mm3 Platelets Greater than or equal to 70,000/mm3Serum creatinine should be normal or near normal.Prior to initiation of INTRON A therapy, CBC and platelet counts should beevaluated in order to establish baselines for monitoring potential toxicity. These testsshould be repeated at Weeks 1 and 2 following initiation of INTRON A therapy, andmonthly thereafter. Serum ALT should be evaluated at approximately 3-month intervalsto assess response to treatment (see DOSAGE AND ADMINISTRATION).Patients with preexisting thyroid abnormalities may be treated if thyroidstimulatinghormone (TSH) levels can be maintained in the normal range by medication.TSH levels must be within normal limits upon initiation of INTRON A treatment and TSHtesting should be repeated at 3 and 6 months (see PRECAUTIONS, LaboratoryTests).INTRON A in combination with REBETOL® is indicated for the treatment ofchronic hepatitis C in patients 3 years of age and older with compensated liver diseasepreviously untreated with alpha interferon therapy and in patients 18 years of age andolder who have relapsed following alpha interferon therapy. See REBETOL prescribinginformation for additional information. Chronic Hepatitis B INTRON A is indicated for the treatment of chronic hepatitis B inpatients 1 year of age or older with compensated liver disease. Patients who have beenserum HBsAg positive for at least 6 months and have evidence of HBV replication(serum HBeAg positive) with elevated serum ALT are candidates for treatment. Studiesin these patients demonstrated that INTRON A therapy can produce virologic remissionof this disease (loss of serum HBeAg) and normalization of serum aminotransferases.INTRON A therapy resulted in the loss of serum HBsAg in some responding patients.Prior to initiation of INTRON A therapy, it is recommended that a liver biopsy beperformed to establish the presence of chronic hepatitis and the extent of liver damage.The physician should establish that the patient has compensated liver disease. Thefollowing patient entrance criteria for compensated liver disease were used in theclinical studies and should be considered before INTRON A treatment of patients withchronic hepatitis B: No history of hepatic encephalopathy, variceal bleeding, ascites, or othersigns of clinical decompensation Bilirubin Normal Albumin Stable and within normal limits Prothrombin Time Adults less than 3 seconds prolongedPediatrics less than or equal to 2 seconds prolonged WBC Greater than or equal to 4000/mm3 Platelets Adults greater than or equal to 100,000/mm3Pediatrics greater than or equal to 150,000/mm3Patients with causes of chronic hepatitis other than chronic hepatitis B or chronichepatitis C should not be treated with INTRON A. CBC and platelet counts should beevaluated prior to initiation of INTRON A therapy in order to establish baselines formonitoring potential toxicity. These tests should be repeated at treatment Weeks 1, 2,4, 8, 12, and 16. Liver function tests, including serum ALT, albumin, and bilirubin,should be evaluated at treatment Weeks 1, 2, 4, 8, 12, and 16. HBeAg, HBsAg, andALT should be evaluated at the end of therapy, as well as 3- and 6-months posttherapy,since patients may become virologic responders during the 6-month periodfollowing the end of treatment. In clinical studies in adults, 39% (15/38) of respondingpatients lost HBeAg 1 to 6 months following the end of INTRON A therapy. Ofresponding patients who lost HBsAg, 58% (7/12) did so 1 to 6 months post-treatment.A transient increase in ALT greater than or equal to 2 times baseline value (flare)can occur during INTRON A therapy for chronic hepatitis B. In clinical trials in adultsand pediatrics, this flare generally occurred 8 to 12 weeks after initiation of therapy andwas more frequent in responders (adults 63%, 24/38; pediatrics 59%, 10/17) than innonresponders (adults 27%, 13/48; pediatrics 35%, 19/55). However, in adults andpediatrics, elevations in bilirubin greater than or equal to 3 mg/dL (greater than or equalto 2 times ULN) occurred infrequently (adults 2%, 2/86; pediatrics 3%, 2/72) duringtherapy. When ALT flare occurs, in general, INTRON A therapy should be continued unless signs and symptoms of liver failure are observed. During ALT flare, clinicalsymptomatology and liver function tests including ALT, prothrombin time, alkalinephosphatase, albumin, and bilirubin, should be monitored at approximately 2-weekintervals (see WARNINGS).
DrugBank Targets:
15
1. Interferon alpha/beta receptor 2;2. Interferon alpha/beta receptor 1
Mechanism of Action:
17
Target: intracellular oncogene expression, natural killer and cytotoxic T-cells, microphage, cytokine production
Action: stimulation, induction (unspecified effects on oncogene expression)
FDA: -
|
| 3 |
|
Keytruda
17
45
|
PEMBROLIZUMAB |
Merck |
September 2014 |
Disease/s that Drug Treats:unresectable or metastatic melanoma
Indications and Usage:
17
KEYTRUDA is a human programmed death receptor-1 (PD-1)-blockingantibody indicated for the treatment of patients with unresectable ormetastatic melanoma and disease progression following ipilimumaband, if BRAF V600 mutation positive, a BRAF inhibitor.This indication is approved under accelerated approval based on tumorresponse rate and durability of response. An improvement in survivalor disease-related symptoms has not yet been established. Continuedapproval for this indication may be contingent upon verification anddescription of clinical benefit in the confirmatory trials. (1)
DrugBank Targets:
15
1. Programmed cell death protein 1
Mechanism of Action:
17
Target: PD-1 receptor
Action: blocks interaction withPD-L1 and PD-L2
FDA: Binding of the PD-1 ligands, PD-L1 and PD-L2, to the PD-1 receptor found on T cells, inhibits T cellproliferation and cytokine production. Upregulation of PD-1 ligands occurs in some tumors and signaling through this pathway can contribute to inhibition of active T-cell immune surveillance of tumors.Pembrolizumab is a monoclonal antibody that binds to the PD-1 receptor and blocks its interaction withPD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including theanti-tumor immune response. In syngeneic mouse tumor models, blocking PD-1 activity resulted indecreased tumor growth.
|
| 4 |
|
Mekinist
17
45
|
TRAMETINIB DIMETHYL SULFOXIDE |
GlaxoSmithKline |
May of 2013 |
Disease/s that Drug Treats:unresectable or metastatic melanoma with BRAF V600E or V600K mutations
Indications and Usage:
17
MEKINIST is a kinase inhibitor indicated as a single agent and incombination with dabrafenib for the treatment of patients with unresectable ormetastatic melanoma with BRAF V600E or V600K mutations as detected byan FDA-approved test. The use in combination is based on the demonstrationof durable response rate. Improvement in disease-related symptoms or overallsurvival has not been demonstrated for MEKINIST in combination withdabrafenib. (1, 14.1)Limitation of use: MEKINIST as a single agent is not indicated for treatmentof patients who have received prior BRAF-inhibitor therapy. (1)
DrugBank Targets:
15
1. Dual specificity mitogen-activated protein kinase kinase 1;2. Dual specificity mitogen-activated protein kinase kinase 2
Mechanism of Action:
17
Target: mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2 activation and of MEK1 and MEK2 kinase
Action: inhibitor
FDA: Trametinib is a reversible inhibitor of mitogen-activated extracellular signal-regulated kinase 1(MEK1) and MEK2 activation and of MEK1 and MEK2 kinase activity. MEK proteins areupstream regulators of the extracellular signal-related kinase (ERK) pathway, which promotescellular proliferation. BRAF V600E mutations result in constitutive activation of the BRAFpathway which includes MEK1 and MEK2. Trametinib inhibits BRAF V600 mutation-positivemelanoma cell growth in vitro and in vivo.Trametinib and dabrafenib target two different tyrosine kinases in the RAS/RAF/MEK/ERKpathway. Use of trametinib and dabrafenib in combination resulted in greater growth inhibitionof BRAF V600 mutation-positive melanoma cell lines in vitro and prolonged inhibition of tumorgrowth in BRAF V600 mutation positive melanoma xenografts compared with either drug alone.
|
| 5 |
|
Odomzo
17
45
|
SONIDEGIB PHOSPHATE |
Novartis |
Jul-15 |
Disease/s that Drug Treats:locally advanced basal cell carcinoma
Indications and Usage:
17
ODOMZO is a hedgehog pathway inhibitor indicated for the treatment ofadult patients with locally advanced basal cell carcinoma (BCC) that hasrecurred following surgery or radiation therapy, or those who are notcandidates for surgery or radiation therapy. (1)
DrugBank Targets:
-
Mechanism of Action:
17
Target: Smoothened
Action: inhibitor
FDA: Sonidegib is an inhibitor of the Hedgehog pathway. Sonidegib binds to and inhibits Smoothened, a transmembrane proteininvolved in Hedgehog signal transduction.
|
| 6 |
|
Opdivo
17
45
|
NIVOLUMAB |
Bristol-Myers Squibb |
March 2015/ December 2014, March 2015 |
Disease/s that Drug Treats:metastatic squamous non-small cell lung cancer/ unresectable or metastatic melanoma, metastatic squamous non-small cell lung cancer
Indications and Usage:
17
OPDIVO is a programmed death receptor-1 (PD-1) blocking antibodyindicated for the treatment of patients with: unresectable or metastatic melanoma and disease progression followingipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. (1.1)This indication is approved under accelerated approval based on tumorresponse rate and durability of response. Continued approval for thisindication may be contingent upon verification and description of clinicalbenefit in the confirmatory trials. (1.1, 14.1) metastatic squamous non-small cell lung cancer with progression on orafter platinum-based chemotherapy. (1.2) , OPDIVO is a programmed death receptor-1 (PD-1) blocking antibody indicated for the treatment of patients with: * unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. (1.1) This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. (1.1, 14.1) * metastatic squamous non-small cell lung cancer with progression on or after platinum-based chemotherapy. (1.2)
DrugBank Targets:
15
1. Programmed cell death protein 1, Programmed cell death protein 1
Mechanism of Action:
17
Target: PD-1 receptor
Action: blocker of interaction with PD-L1 and PD-L2, blocks its interaction with PD-L1 and PD-L2
FDA: Binding of the PD-1 ligands, PD-L1 and PD-L2, to the PD-1 receptor found on T cells, inhibitsT-cell proliferation and cytokine production. Upregulation of PD-1 ligands occurs in sometumors and signaling through this pathway can contribute to inhibition of active T-cell immunesurveillance of tumors. Nivolumab is a human immunoglobulin G4 (IgG4) monoclonal antibodythat binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1pathway-mediated inhibition of the immune response, including the anti-tumor immuneresponse. In syngeneic mouse tumor models, blocking PD-1 activity resulted in decreased tumorgrowth. , Binding of the PD-1 ligands, PD-L1 and PD-L2, to the PD-1 receptor found on T cells, inhibits T-cell proliferation and cytokine production. Upregulation of PD-1 ligands occurs in some tumors and signaling through this pathway can contribute to inhibition of active T-cell immune surveillance of tumors. Nivolumab is a human immunoglobulin G4 (IgG4) monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response. In syngeneic mouse tumor models, blocking PD-1 activity resulted in decreased tumor growth.
|
| 7 |
|
Proleukin
17
45
|
ALDESLEUKIN |
Chiron |
January 1998 |
Disease/s that Drug Treats:Metastatic melanoma
Indications and Usage:
17
Proleukin® (aldesleukin) is indicated for the treatment of adults with metastatic renal cellcarcinoma (metastatic RCC).Proleukin is indicated for the treatment of adults with metastatic melanoma.Careful patient selection is mandatory prior to the administration of Proleukin. SeeâCONTRAINDICATIONSâ, âWARNINGSâ and âPRECAUTIONSâ sections regarding patientscreening, including recommended cardiac and pulmonary function tests and laboratorytests.Evaluation of clinical studies to date reveals that patients with more favorable ECOGperformance status (ECOG PS 0) at treatment initiation respond better to Proleukin, with ahigher response rate and lower toxicity (See âCLINICAL PHARMACOLOGYâ section,âCLINICAL STUDIESâ section and âADVERSE REACTIONSâ section). Therefore, selectionof patients for treatment should include assessment of performance status.Experience in patients with ECOG PS >1 is extremely limited.
DrugBank Targets:
15
1. Interleukin-2 receptor subunit beta;2. Interleukin-2 receptor subunit alpha;3. Cytokine receptor common subunit gamma
Mechanism of Action:
17
Target: human cells
Action: enhancer of immune response and strnaght ( lymphocytemitogenesis, growth of human interleukin-2 dependent cell lines, lymphocyte cytotoxicity, induction of killer cell activity and interferon-gamma production)
FDA: Proleukin® (aldesleukin) has been shown to possess the biological activities of human nativeinterleukin-2.1,2 In vitro studies performed on human cell lines demonstrate theimmunoregulatory properties of Proleukin, including: a) enhancement of lymphocytemitogenesis and stimulation of long-term growth of human interleukin-2 dependent cell lines;b) enhancement of lymphocyte cytotoxicity; c) induction of killer cell (lymphokine-activated(LAK) and natural (NK)) activity; and d) induction of interferon-gamma production.The in vivo administration of Proleukin in animals and humans produces multipleimmunological effects in a dose dependent manner. These effects include activation ofcellular immunity with profound lymphocytosis, eosinophilia, and thrombocytopenia, and theproduction of cytokines including tumor necrosis factor, IL-1 and gamma interferon. 3 In vivoexperiments in murine tumor models have shown inhibition of tumor growth.4 The exactmechanism by which Proleukin mediates its antitumor activity in animals and humans isunknown.
|
| 8 |
|
Sylatron
17
45
|
PEGINTERFERON ALFA-2B |
Merck |
April 2011 |
Disease/s that Drug Treats:melanoma
Indications and Usage:
17
PegIntron is an antiviral indicated for treatment of Chronic Hepatitis C(CHC) in patients with compensated liver disease. (1.1)
DrugBank Targets:
15
1. Interferon alpha/beta receptor 1;2. Interferon alpha/beta receptor 2
Mechanism of Action:
17
Target: innate antiviral immune response
Action: inducer
FDA: Pegylated recombinant human interferon alfa-2b is an inducer of the innate antiviral immune response [see Microbiology (12.4)].
|
| 9 |
|
Tafinlar
17
45
|
DABRAFENIB MESYLATE |
GlaxoSmithKline |
May 2013 |
Disease/s that Drug Treats:unresectable or metastatic melanoma with BRAF V600E mutation
Indications and Usage:
17
TAFINLAR is a kinase inhibitor indicated as a single agent for thetreatment of patients with unresectable or metastatic melanoma withBRAF V600E mutation as detected by an FDA-approved test. (1.1, 2.1) TAFINLAR in combination with trametinib is indicated for the treatmentof patients with unresectable or metastatic melanoma with BRAF V600Eor V600K mutations as detected by an FDA-approved test. The use incombination is based on the demonstration of durable response rate.Improvement in disease-related symptoms or overall survival has notbeen demonstrated for TAFINLAR in combination with trametinib. (1.2,2.1, 14.2)Limitation of Use: TAFINLAR is not indicated for treatment of patients withwild-type BRAF melanoma. (1.3, 5.2)
DrugBank Targets:
15
1. Serine/threonine-protein kinase B-raf;2. RAF proto-oncogene serine/threonine-protein kinase;3. Serine/threonine-protein kinase SIK1;4. Serine/threonine-protein kinase Nek11;5. LIM domain kinase 1
Mechanism of Action:
17
Target: some mutated forms of BRAF kinases, wild-type BRAF and CRAF kinases
Action: inhibitor
FDA: Dabrafenib is an inhibitor of some mutated forms of BRAF kinases with in vitro IC50 values of0.65, 0.5, and 1.84 nM for BRAF V600E, BRAF V600K, and BRAF V600D enzymes,respectively. Dabrafenib also inhibits wild-type BRAF and CRAF kinases with IC50 values of 3.2and 5.0 nM, respectively, and other kinases such as SIK1, NEK11, and LIMK1 at higherconcentrations. Some mutations in the BRAF gene, including those that result in BRAF V600E,can result in constitutively activated BRAF kinases that may stimulate tumor cell growth [seeIndications and Usage (1)]. Dabrafenib inhibits BRAF V600 mutation-positive melanoma cellgrowth in vitro and in vivo.Dabrafenib and trametinib target two different tyrosine kinases in the RAS/RAF/MEK/ERKpathway. Use of dabrafenib and trametinib in combination resulted in greater growth inhibitionof BRAF V600 mutation-positive melanoma cell lines in vitro and prolonged inhibition of tumorgrowth in BRAF V600 mutation positive melanoma xenografts compared with either drug alone.
|
| 10 |
|
Yervoy
17
45
|
IPILIMUMAB |
Bristol-Myers Squibb |
March 2011 |
Disease/s that Drug Treats:metastatic melanoma
Indications and Usage:
17
YERVOY is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blockingantibody indicated for the treatment of unresectable or metastaticmelanoma. (1)
DrugBank Targets:
15
1. Cytotoxic T-lymphocyte protein 4
Mechanism of Action:
17
Target: CTLA-4
Action: blocker of interation with CD80/CD86
FDA: CTLA-4 is a negative regulator of T-cell activity. Ipilimumab is a monoclonal antibody thatbinds to CTLA-4 and blocks the interaction of CTLA-4 with its ligands, CD80/CD86. Blockadeof CTLA-4 has been shown to augment T-cell activation and proliferation, including theactivation and proliferation of tumor infiltrating T-effector cells. Inhibition of CTLA-4 signalingcan also reduce T-regulatory cell function, which may contribute to a general increase in T cellresponsiveness, including the anti-tumor immune response.
|
| 11 |
|
Zelboraf
17
45
|
VEMURAFENIB |
Roche |
August of 2011 |
Disease/s that Drug Treats:BRAF + melanoma
Indications and Usage:
17
ZELBORAF® is a kinase inhibitor indicated for the treatment of patients withunresectable or metastatic melanoma with BRAF V600E mutation as detectedby an FDA-approved test. (1, 2.1)Limitation of Use: ZELBORAF is not indicated for treatment of patients withwild-type BRAF melanoma. (2.1, 5.2)
DrugBank Targets:
15
1. Serine/threonine-protein kinase B-raf
Mechanism of Action:
17
Target: some mutated forms of BRAF serinethreoninekinase
Action: inhibitor
FDA: Vemurafenib is a low molecular weight, orally available inhibitor of some mutated forms of BRAF serinethreoninekinase, including BRAF V600E. Vemurafenib also inhibits other kinases in vitro such as CRAF,ARAF, wild-type BRAF, SRMS, ACK1, MAP4K5, and FGR at similar concentrations. Some mutations in theBRAF gene including V600E result in constitutively activated BRAF proteins, which can cause cellproliferation in the absence of growth factors that would normally be required for proliferation. Vemurafenibhas anti-tumor effects in cellular and animal models of melanomas with mutated BRAF V600E.
|
Drugs for Melanoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 629)
| # |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
| 1 |
|
Cisplatin |
Approved |
Phase 4,Phase 3,Phase 2,Phase 1 |
|
15663-27-1 |
2767
441203
84093
|
|
Synonyms:
(SP-4-1)-diamminedichloridoplatinum
(SP-4-1)-diamminedichloroplatinum
(SP-4-2)-diamminedichloridoplatinum
(SP-4-2)-diamminedichloroplatinum
Abiplatin
Biocisplatinum
Briplatin
CACP
Carboquone
CDDP
CHEBI:35852
CID441203
Cis Pt II
cis-[PtCl2(NH3)2]
cis-DDP
Cis-DDP
Cis-Diaminedichloroplatinum
cis-diamminedichloridoplatinum(II)
cis-Diamminedichloroplatinum
Cis-Diamminedichloroplatinum
cis-diamminedichloroplatinum(II)
cis-Dichlorodiammineplatinum(II)
Cismaplat
Cisplatine
Cisplatino
Cisplatinum
Cisplatyl
Citoplationo
CPD0-1392
CPDC
|
CPDD
DB00515
DDP
DDPT
Diamminedichloroplatinum
EU-0100918
Lederplatin
nchembio773-comp1
Neoplatin
Peyrone's chloride
Peyrone's salt
Plastin
Platamine
Platiblastin
Platidiam
Platinex
Platinol
Platinol-AQ
Platinoxan
Platinum Ammine Chloride
Platinum Ammonium Chloride
Platinum Diamine Dichloride
Randa
Trans-DDP
Trans-Diaminedichloroplatinum
trans-diamminedichloridoplatinum(II)
Trans-Diamminedichloroplatinum
Trans-Dichlorodiammine Platinum
Trans-Platinumdiammine Dichloride
|
|
| 2 |
|
Dacarbazine |
Approved, Investigational |
Phase 4,Phase 3,Phase 2,Phase 1 |
|
4342-03-4 |
5351166
|
|
Synonyms:
(5E)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide
(5Z)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide
(Dimethyltriazeno)imidazolecarboxamide
37626-23-6
4-(3,3-dimethyl-1-triazeno)imidazole-5-carboxamide
4-(3,3-Dimethyl-1-triazeno)imidazole-5-carboxamide
4-(3,3-Dimethyltriazeno)imidazole-5-carboxamide
4(5)-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide
4-(5)-(3,3-dimethyl-1-triazeno)imidazole-5(4)-carboxamide
4(5)-(3,3-Dimethyl-1-triazeno)imidazole-5(4)-carboxamide
4-(5)-(3,3-Dimethyl-1-triazeno)imidazole-5(4)-carboxamide
4-(Dimethyltriazeno)imidazole-5-c arboxamide
4-(dimethyltriazeno)imidazole-5-carboxamide
4-(Dimethyltriazeno)imidazole-5-carboxamide
4-(or 5)-(3,3-Dimethyl-1-triazeno)imidazole-5(or 4)-carboxamide
4-(or 5)-(3,3-Dimethyl-1-triazeno)imidazole-5(or 4)-carboxamide
4-[(1E)-3,3-Dimethyltriaz-1-en-1-yl]-1H-imidazole-5-carboxamide
4-[3,3-dimethyltriaz-1-en-1-yl]-1H-imidazole-5-carboxamide
4342-03-4
5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide
5-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide
5-(3,3-Dimethyl-1-triazenyl)-1H-imidazole-4-carboxamide
5-(3,3-Dimethyl-1-triazenyl)imidazole-4-carboxamide
5-(3,3-Dimethyltri azeno)imidazole-4-carboxamide
5-(3,3-dimethyltriaz-1-en-1-yl)-1H-imidazole-4-carboxamide
5-(3,3-Dimethyltriazeno)-imidazole-4-carbamide
5-(3,3-dimethyltriazeno)imidazole-4-carboxamide
5-(3,3-Dimethyltriazeno)imidazole-4-carboxamide
5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide
5-(Dimethyltriazeno)-4-imidazolecarboxamide
5-(dimethyltriazeno)imidazole-4-carboxamide
5-(Dimethyltriazeno)imidazole-4-carboxamide
5-(Dimethyltriazeno)imidazole-4-carboximide
5(or 4)-(dimethyltriazeno)imidazol e-4(or 5)-carboxamide
5(or 4)-(dimethyltriazeno)imidazole-4(or 5)-carboxamide
5-[3,3-Dimethyl-1-triazenyl]imidazole-4-carboxamide
94361-71-4
AC1NQXVV
AC1NS01W
AC1NS4BN
AI3-52825
Biocarbazin
Biocarbazine
Biocarbazine R
BPBio1_000428
BRD-K35520305-001-07-8
BSPBio_000388
BSPBio_002091
C6H10N6O
Carboxamide, Dimethyl Imidazole
CAS-891986
CCRIS 190
CHEBI:4305
CHEMBL476
CID5281007
CID5351166
CID5353562
D00288
D003606
D2390_SIGMA
D3634
Dacarbazin
Dacarbazina
dacarbazine
Dacarbazine
Dacarbazine (JAN/USP/INN)
Dacarbazine [USAN:INN:BAN:JAN]
Dacarbazino
Dacarbazino [INN-Spanish]
Dacarbazinum
Dacarbazinum [INN-Latin]
Dacatic
DB00851
Decarbazine
Deticene
DIC
|
Dimethyl Imidazole Carboxamide
Dimethyl Triazeno Imidazole Carboxamide
Dimethyltriazenoimidazolecarboxamide
Di-methyl-triazenoimidazolecarboxamide
Di-me-triazenoimidazolecarboxamide
DivK1c_000326
DTIC
DTIC Dome
DTIC, DTIC-Dome, Dacarbazine
Dtic-Dome
DTICDome
DTIC-Dome
Dtic-Dome (TN)
DTIE
EINECS 224-396-1
HE1150000
HMS1569D10
HMS2090A20
HMS2091I20
HMS501A08
HSDB 3219
I06-2280
I14-1659
ICDMT
ICDT
IDI1_000326
Imidazole carboxamide
Imidazole Carboxamide
Imidazole Carboxamide, Dimethyl
KBio1_000326
KBio2_001364
KBio2_003932
KBio2_006500
KBio3_001311
KBioGR_000896
KBioSS_001364
LS-119
MLS001332543
MLS001332544
MolPort-003-666-153
MolPort-003-846-120
MolPort-006-709-420
NCGC00016986-01
NCGC00091861-01
NCGC00091861-02
NCGC00091861-03
NCGC00091861-04
NCI60_004053
NCI-C04717
NCIMech_000261
NINDS_000326
NIOSH/HE1150000
NPFAPI-05
NSC 45388
NSC45388
NSC-45388
Prestwick_904
Prestwick0_000574
Prestwick1_000574
Prestwick2_000574
Prestwick3_000574
S1221_Selleck
SMP2_000251
SMR000857131
SPBio_001075
SPBio_002607
Spectrum_000884
SPECTRUM1500218
Spectrum2_001148
Spectrum3_000366
Spectrum4_000308
Spectrum5_000823
ST51014976
UNII-7GR28W0FJI
WLN: T5M CNJ DVZ ENUNN1&1
|
|
| 3 |
|
Vindesine |
Approved, Investigational |
Phase 4 |
|
53643-48-4, 59917-39-4 |
40839
|
|
Synonyms:
3-(aminocarbonyl)-O(4)-deacetyl-3-de(methoxycarbonyl)vincaleukoblastine
3-(Aminocarbonyl)-O(4)-deacetyl-3-de(methoxycarbonyl)vincaleukoblastine
3-(Aminocarbonyl)-O(sup 4)-deacetyl-3-de(methoxycarbonyl)vincaleukoblastine
3-Carbamoyl-4-deacetyl-3-de(methoxycarbonyl)vincaleukoblastine
3-carbamoyl-O(4)-deacetyl-3-de(methoxycarbonyl)vincaleukoblastine
53643-48-4
AC1L24KY
C43H55N5O7
CHEBI:36373
CHEMBL219146
CID40839
D06304
DAVA
DB00309
Desacetylvinblastine amide
Desacetylvinblastine Amide Sulfate
EINECS 258-682-2
Eldesine
Eldisine
HMS2090E15
|
HSDB 6961
Lilly 112531
LS-162145
methyl (5S,7S,9S)-9-[(2b,3b,4b,5a,12b,19a)-3-carbamoyl-3,4-dihydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidin-15-yl]-5-ethyl-5-hydroxy-1,4,5,6,7,8,9,10-octahydro-2H-3,7-methanoazacycloundecino[5,4-b]indole-9-carboxylate
methyl (5S,7S,9S)-9-[(2beta,3beta,4beta,5alpha,12beta,19alpha)-3-carbamoyl-3,4-dihydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidin-15-yl]-5-ethyl-5-hydroxy-1,4,5,6,7,8,9,10-octahydro-2H-3,7-methanoazacycloundecino[5,4-b]indole-9-carboxylate
MolPort-005-933-570
NSC-245467
STOCK1N-75293
UNII-RSA8KO39WH
Vindesin
Vindesina
Vindesina [INN-Spanish]
vindesine
Vindesine (USAN/INN)
Vindesine [USAN:BAN:INN]
Vindesine [USAN:INN:BAN]
Vindesine Sulfate
Vindesinum
Vindesinum [INN-Latin]
|
|
| 4 |
|
Ranibizumab |
Approved |
Phase 4,Phase 2,Phase 3,Phase 1 |
|
347396-82-1 |
459903
|
|
Synonyms:
347396-82-1
D05697
Lucentis
Lucentis (TN)
ranibizumab
|
Ranibizumab
Ranibizumab (genetical recombination)
Ranibizumab (genetical recombination) (JAN)
Ranibizumab (USAN/INN)
rhuFab V2
|
|
| 5 |
|
Imiquimod |
Approved, Investigational |
Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 |
|
99011-02-6 |
57469
|
|
Synonyms:
1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine
1-(2-Methylpropyl)-1H-imidazole[4,5-c]quinoline-4-amine
1-(2-methylpropyl)imidazo[4,5-c]quinolin-4-amine
1-isobutyl-1H-imidazo(4,5-c)quinolin-4-amine
1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
1-Isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
3M Brand of Imiquimod
4-Amino-1-isobutyl-1H-imidazo(4,5-c)quinoline
4-Amino-1-isobutyl-1H-imidazo[4,5-c]quinoline
99011-02-6
AC1L1N2I
AC1Q4YO9
AC-529
Aldara
Aldara (TN)
Aldara, Imiquimod
BB_SC-2107
Beselna
BIDD:GT0859
C056493
CHEBI:36704
CHEMBL1282
CID57469
D02500
DB00724
DZ-2636
FT-0080222
HMS2090M14
I06-0624
|
I06-2289
I0747
I5159_SIGMA
imiquimod
Imiquimod
IMIQUIMOD
Imiquimod (JAN/USAN/INN)
Imiquimod [USAN:INN]
Imiquimod acetate
Imiquimodum
LS-178395
MLS000083577
MolPort-002-507-845
MTD-39
NCGC00070736-02
NSC369100
R 837
R-837
S 26308
S1211_Selleck
S-26308
SMR000048307
STK583860
TL8006059
TMX-101
UNII-P1QW714R7M
Zartra
ZINC19632912
Zyclara
|
|
| 6 |
|
Trametinib |
Approved |
Phase 4,Phase 3,Phase 2,Phase 1 |
|
871700-17-3 |
11707110
|
|
Synonyms:
GSK 1120212
GSK1120212
JTP-74057
MEK Inhibitor GSK1120212
|
Mekinist
trametinib
Trametinib Dimethyl Sulfoxide
Trametinibum
|
|
| 7 |
|
Somatostatin |
Approved, Investigational |
Phase 4,Phase 3,Phase 2,Phase 1 |
|
38916-34-6, 51110-01-1 |
53481605
|
|
Synonyms:
growth hormone-inhibiting hormone (GHIH)
somatotropin release-inhibiting factor (SRIF)
|
somatotropin release-inhibiting hormone
|
|
| 8 |
|
nivolumab |
Approved |
Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 |
|
946414-94-4 |
|
|
Synonyms:
|
| 9 |
|
Triamcinolone |
Approved, Vet_approved |
Phase 4,Phase 2,Phase 3 |
|
124-94-7 |
31307
|
|
Synonyms:
(8S,9R,10S,11S,13S,14S,16R,17S)-9-fluoro-11,16,17-trihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
11.Beta.,16.alpha.,17.alpha., 21-Tetrahydroxy-9.alpha.-fluoro-1,4-pregnadiene-3,20-dione
11.beta.,16.alpha.,17.alpha.,21-Tetrahydroxy-9.alpha.-fluoro-1,4-pregnadiene-3,20-dione
11-beta,16-alpha,17-alpha,21-Tetrahydroxy-9-alpha-fluoro-1,4-pregnadiene-3,20-dione
11β,16α,17α,21-tetrahydroxy-9α-fluoro-1,4-pregnadiene-3,20-dione
124-94-7
4-08-00-03629 (Beilstein Handbook Reference)
83474-03-7
9.Alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahy
9.alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahydroxy-1,4-pregnadiene-3,20-dione
9.alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9.Alpha.-Fluoro-11.beta.,16.alpha.,17.alpha., 21-tetrahydroxypregna-1,4-diene-3,20-d
9.alpha.-Fluoro-11.beta.,16.alpha.,17.alpha.,21-tetrahydroxypregna-1,4-diene-3,20-dione
9.alpha.-Fluoro-16.alpha.-hydroxyprednisolone
9alpha-Fluoro-11beta,16alpha,17,21-tetrahydroxy-1,4-pregnadiene-3,20-dione
9alpha-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9-alpha-Fluoro-11-beta,16-alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9alpha-Fluoro-16alpha-hydroxyprednisolone
9-alpha-Fluoro-16-alpha-hydroxyprednisolone
9-Fluoro-11,16,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9-fluoro-11β,16α,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9α-fluoro-11β,16α,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9α-fluoro-11β,16α,17α,21-tetrahydroxypregna-1,4-diene-3,20-dione
9α-fluoro-16α-hydroxyprednisolone
AC1L1LDH
AC1Q5HJC
AC-2072
Adcortyl
Aristocort
Aristocort A
Aristocort Tablets
Aristogel
Aristospan
Azmacort
Bio-0662
BPBio1_000154
BRD-K77554836-001-03-3
BRN 2341955
BSPBio_000140
C21H27FO6
Celeste
CHEMBL1451
CID31307
Cinolone
Cinolone-T
CL 19823
D00385
D014221
DB00620
Delphicort
droxypregna-1,4-diene-3,20-dione
EINECS 204-718-7
EU-0101179
Fluoxiprednisolone
Fluoxyprednisolone
Flutex
Fougera
HMS1568G22
HMS2090D12
HSDB 3194
ione
Kenacort
Kenacort (TN)
Kenacort-A
Kenacort-Ag
Kenacort-AG
Kenalog
Kenalog in Orabase
Kenalog-10
Kenalog-40
Kenalog-H
Ledercort
Lopac0_001179
|
LS-698
MLS000028542
MLS001066543
MLS002695935
MolPort-002-528-981
Mycolog
Nasacort
Nasacort Aq
Nasacort Hfa
NCGC00021580-03
NCGC00021580-04
NCGC00021580-05
NCGC00021580-06
NCGC00021580-07
nchembio.2007.53-comp7
NCI60_000750
NSC 13397
NSC13397
Omcilon
Omicilon
Oracort
Oralone
Orion
Polcortolon
Pregna-1,4-diene-3,20-dio
Pregna-1,4-diene-3,20-dione, 9-fluoro-11,16,17,21-tetrahydroxy-, (11beta,16alpha)
Pregna-1,4-diene-3,20-dione, 9-fluoro-11beta,16alpha,17,21-tetrahydroxy- (8CI)
Prestwick_438
Prestwick0_000120
Prestwick1_000120
Prestwick2_000120
Prestwick3_000120
Rodinolone
S1933_Selleck
Sk-Triamcinolone
SK-Triamcinolone
SMP1_000300
SMR000058333
SPBio_002079
T6376_SIGMA
Tiamcinolonum
Tiamcinolonum [INN-Latin]
Triacet
Triacort
Triamcet
Triamcinalone
Triamcinlon
Triamcinolon
Triamcinolona
Triamcinolona [INN-Spanish]
triamcinolone
Triamcinolone (JP15/USP/INN)
TRIAMCINOLONE (SEE ALSO TRIAMCINOLONE ACETONIDE (76-25-5) AND TRIAMCINOLONE DIACETATE (67-78-7))
Triamcinolone [USAN:INN:BAN:JAN]
Triamcinolone acetonide
Triamcinolone diacetate
Triamcinolone hexacetonide
Triamcinolonum
Triamcinolonum [INN]
Triam-Tablinen
Triatex
Tricortale
Triderm
Trilone
Tri-Nasal
Tristoject
Trymex
UNII-1ZK20VI6TY
Vetalog
Volon
Volon A
WLN: L E5 B666 OV KU MUTJ A1 BF CQ E1 FV1Q FQ GQ
ZINC03882036
|
|
| 10 |
|
Everolimus |
Approved |
Phase 4,Phase 2,Phase 1 |
|
159351-69-6 |
6442177
|
|
Synonyms:
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,23S,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriacont
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34as)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethy
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-3-{(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl}-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
07741_FLUKA
159351-69-6
40-O-(2-hydroxyethyl)-rapamycin
42-O-(2-Hydroxyethyl)rapamycin
Afinitor
Certican
CERTICAN(R)
CHEMBL1201755
D02714
DB01590
everolimus
|
Everolimus
Everolimus (JAN/USAN/INN)
Everolimus [USAN]
LS-143292
MolPort-003-847-342
MolPort-003-925-588
NCGC00167512-01
NVP-RAD-001
RAD 001
RAD001
RAD-001
RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus
RAD-001C
S1120_Selleck
SDZ-RAD
UNII-9HW64Q8G6G
Zortress
|
|
| 11 |
|
Miconazole |
Approved, Investigational, Vet_approved |
Phase 4,Phase 2,Phase 1 |
|
22916-47-8 |
4189
|
|
Synonyms:
(+-)-1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl) imidazole
1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole
1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole
1-[2-(2,4-Dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole
1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole
1-[2-(2,4-dichlorophenyl)-2-{[(2,4-dichlorophenyl)methyl]oxy}ethyl]-1H-imidazole
1-[2,4-Dichloro- beta-([2,4-dichloro- benzyl]oxy)phenethyl]imidazole
1-{2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole
22832-87-7 (NITRATE)
22916-47-8
75319-47-0
AB00053500
AC1L1HM1
Aflorix(nitrate)
AKOS001574474
Albistat(nitrate)
Andergin(nitrate)
BPBio1_000279
BRD-A82396632-001-03-0
BRD-A82396632-008-02-7
BRN 0965511
BSPBio_000253
BSPBio_002033
CCRIS 7924
CHEBI:6923
CHEMBL91
CID4189
Conofite(nitrate)
CPD-4501
D00416
Dactarin
Daktarin iv
Daktarin IV
DB01110
DivK1c_000156
EINECS 245-324-5
Epi-Monistat(nitrate)
Femizol-M
Florid(nitrate)
Gyno-Daktar(nitrate)
HMS1568M15
HMS2090B21
I14-14342
IDI1_000156
imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl) methoxy)ethyl)- (9CI)
Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)- (9CI)
KBio1_000156
KBio2_001445
KBio2_004013
KBio2_006581
KBio3_001533
KBioGR_000581
KBioSS_001445
Lotrimin AF(nitrate)
LS-78378
MCZ
Micantin (nitrate)
Miconasil Nitrate
Miconazol
Miconazol [INN-Spanish]
|
miconazole
Miconazole
Miconazole (JP15/USP/INN)
Miconazole [USAN:BAN:INN:JAN]
Miconazole 3
Miconazole 3 Combination Pack
Miconazole 7 Combination Pack
Miconazole nitrate salt
Miconazole-7
Miconazolo
Miconazolo [DCIT]
Miconazolum
Miconazolum [INN-Latin]
Micozole
Minostate
MJR 1762
MLS002222203
MolPort-002-557-553
Monazole 7
Monista (nitrate)
Monistat
Monistat (TN)
Monistat 1 Combination Pack
Monistat 3 Dual-Pak
Monistat 3 Vaginal Ovules
Monistat 5 Tampon
Monistat 7 Dual-Pak
Monistat 7 Vaginal Suppositories
Monistat Dual- PAK
Monistat IV
Monistat iv (tn)
Monistat iv (TN)
Monistat-Derm
NCI60_001353
NCI60_001380
NINDS_000156
Novo-Miconazole Vaginal Ovules
NSC 170986
NSC169434
NSC170986
Oprea1_091955
Prestwick_335
Prestwick0_000067
Prestwick1_000067
Prestwick2_000067
Prestwick3_000067
R 18134
R-14,889
SMR001307249
SPBio_000976
SPBio_002174
Spectrum_000965
Spectrum2_001048
Spectrum3_000507
Spectrum4_000061
Spectrum5_001297
STK834405
STOCK1S-93556
UNII-7NNO0D7S5M
Vusion
Zimycan
|
|
| 12 |
|
Sirolimus |
Approved, Investigational |
Phase 4,Phase 2,Phase 1 |
|
53123-88-9 |
46835353
6436030
5284616
|
|
Synonyms:
(-)-rapamycin
(-)-Rapamycin
1fkb
1pbk
23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine
23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine
23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29
3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
53123-88-9
A422989, NSC226080
AC1L1JH9
AC1L7MJ9
AC1L9ZMV
AC-722
Ambotz53123-88-9
Antibiotic AY 22989
AY 22989
AY22989
AY-22989
BIDD:PXR0165
Bio1_000293
Bio1_000782
Bio1_001271
Bio2_000375
Bio2_000855
BiomolKI2_000084
C07909
C51H79NO13
CBiol_002007
CCRIS 9024
CHEBI:100923
CHEBI:9168
CHEMBL413
CID10213190
CID10795871
CID11949238
CID11959112
CID313006
CID478951
CID5040
CID5284616
CID5358081
CID5374464
CID5460439
CID5497196
CID5924240
CID6436030
CID6610270
CID6610346
CID6711160
CID6713081
CID9833581
CID9854379
CID9854380
CID9962926
CID9962928
D00753
DB00877
DE-109
DivK1c_006936
FT-0082351
heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy
|
HMS2089A21
HSDB 7284
KBio1_001880
KBio2_000410
KBio2_002978
KBio2_005546
KBio3_000779
KBio3_000780
KBioGR_000410
KBioSS_000410
LCP-Siro
LMPK06000003
LS-143290
MLS000028373
MolMap_000043
MolPort-003-959-433
MS-R001
NCGC00021305-05
nchembio.100-comp4
nchembio.2007.42-comp2
nchembio.79-comp1
nchembio762-comp1
nchembio883-comp3
NCI60_001851
NCIMech_000355
NSC 226080
NSC226080
Perceiva
QTL1_000069
R0395_SIAL
R0395_SIGMA
RAP
RAPA
Rapammune
Rapamune
Rapamune (TN)
rapamycin
Rapamycin
Rapamycin (TN)
Rapamycin C-7, analog 4
Rapamycin from Streptomyces hygroscopicus
Rapamycin Immunosuppressant Drug
RPM
S1039_Selleck
SIIA 9268A
SILA 9268A
SILA9268A
sirolimus
Sirolimus
sirolimús
Sirolimus (RAPAMUNE)
Sirolimus (USAN/INN)
Sirolimus [USAN:BAN:INN]
Sirolimus, Rapamune,Rapamycin
sirolimusum
SMP1_000255
SMR000058564
SpecPlus_000840
UNII-W36ZG6FT64
UNM-0000358684
Wy 090217
WY-090217
|
|
| 13 |
|
Sorafenib |
Approved, Investigational |
Phase 4,Phase 3,Phase 1,Phase 2 |
|
284461-73-0 |
216239
406563
|
|
Synonyms:
284461-73-0
4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide
4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate
4-(4-{3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide
4(4-{3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide
4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide
4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide
4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide
4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide
4-{4-[({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]AMINO}CARBONYL)AMINO]PHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE
AB1004622
AC-1674
AC1L50CF
BAX
BAY 439006
BAY 43-9006
BAY 43-9006 (free base)
BAY 43-9006 tosylate salt
BAY 54-9085 (tosylate salt)
BAY-43-0006
BAY43-9006
BAY-43-9006
BAY-54-9085
Bio-0100
BRD-K23984367-001-01-8
CHEBI:47228
CHEBI:50924
CHEMBL1336
CID216239
D08524
|
DB00398
DB07438
EN002709
I06-0856
K00597a
Kinome_766
LS-186067
LS-187021
LS-187788
MolPort-003-850-270
N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcar bamoyl)-4-pyridyloxy)phenyl)urea
N-(4-Chloro-3-(trifluoromethyl)phenyl)-n'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea
N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea
N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea
NCGC00167488-01
nchembio.117-comp17
Nexavar
NSC-724772
NSC747971
sorafenib
Sorafenib
Sorafenib (INN)
Sorafenib [INN]
Sorafenib tosylate
sorafenibum
Sorafenibum
STK627350
UNII-9ZOQ3TZI87
ZINC01493878
|
|
| 14 |
|
Sunitinib |
Approved, Investigational |
Phase 4,Phase 2,Phase 1 |
|
341031-54-7, 557795-19-4 |
5329102
|
|
Synonyms:
(2S)-2-hydroxybutanedioic acid
1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-, (2S)-hydroxybutanedioate (1:1)
1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-, (2S)-hydroxybutanedioate (1:1)
326914-13-0
341031-54-7
5-(5-FLUORO-2-OXO-1,2-DIHYDRO-INDOL-3-YLIDENEMETHYL)-2,4-DIMETHYL-1H-PYRROLE-3-CARBOXYLIC ACID (2-DIETHYLAMINO-ETHYL)-AMIDE
557795-19-4
AC1NS62J
AC1O5CMQ
AKOS005145765
Butanedioic acid, hydroxy-, (2S)-, compd. with N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (1:1)
CHEBI:38940
CHEBI:550864
CHEMBL1567
CHEMBL535
CID5329102
CID6456015
D06402
D08552
DB01268
DB07417
EN002687
FT-0083555
FT-0083556
I01-1229
K00588a
KS-5022
LS-186078
LS-187023
LS-187648
MolPort-003-986-763
N-(2-(Diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (2S)-hydroxybutanedioate
N-(2-diethylaminoethyl)-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
NCGC00164631-01
NSC736511
|
NSC750690
PDGF TK antagonist
PHA-290940AD
PNU-290940AD
S1042_Selleck
ST51053712
SU 011248
SU 11248
SU010398
SU-010398
Su-011248
SU011248
SU011248 L-malate salt
SU-011248 L-malate salt
SU11248
SU-11248
SU-11248 L-malate salt
SU-11248J
SU-12662
Sunitanib
sunitinib
Sunitinib
Sunitinib (free base)
Sunitinib (INN)
Sunitinib malate
Sunitinib malate (JAN/USAN)
Sunitinib malate [USAN]
sunitinibum
Sunitinibum
Sutent
Sutent (TN)
Sutent, SU-11248
TL8002546
UNII-LVX8N1UT73
UNII-V99T50803M
|
|
| 15 |
|
Aldesleukin |
Approved |
Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 |
|
110942-02-4, 85898-30-2 |
|
|
Synonyms:
125-L-serine-2-133-interleukin 2 (human reduced)
Interleukin-2 aldesleukin
|
Interleukin-2(2-133),125-ser
Recombinant interleukin-2 human
|
|
| 16 |
|
Etanercept |
Approved, Investigational |
Phase 4 |
|
185243-69-0 |
|
|
Synonyms:
185243-69-0
CD120b
D00742
Enbrel
Enbrel (TN)
Enbrel Sureclick
etanercept
Etanercept
Etanercept (genetical recombination)
Etanercept (genetical recombination) (JAN)
Etanercept (USAN/INN)
|
Etanercept-szzs
p75
p80 TNF-alpha receptor
RHU TNFR:FC
RHU-TNFR:FC
TNF-R2
TNFR-Immunoadhesin
Tumor necrosis factor receptor 2
Tumor necrosis factor receptor superfamily member 1B precursor
Tumor necrosis factor receptor type II
|
|
| 17 |
|
Citalopram |
Approved |
Phase 4 |
|
59729-33-8 |
2771
|
|
Synonyms:
[3H]Citalopram
1-(3-(Dimethylamino)propyl)-1-(p-fluorophenyl)-5-phthalancarbonitrile
1,3-dihydro[3,4]benzofuran-5-carbonitrile
1,3-Dihydro-1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-5-isobenzofurancarbonitrile
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3H-2-benzofuran-5-carbonitrile
59729-33-8
AB00513896
AC-12214
AC1L1EFH
AE-641/00603021
Akarin
Bonitrile
BPBio1_000929
BRD-A47598013-004-02-0
BSPBio_000843
C07572
C20H21FN2O
Celapram
Celexa
Celius
CHEBI:3723
CHEMBL549
Ciazil
CID2771
Cilift
Cipram
Cipramil
Ciprapine
Citabax
Citadur
Citadur (TN)
Citalec
citalopram
Citalopram (USP/INN)
Citalopram [Celexa]
Citalopram [INN:BAN]
Citalopram hydrobromide
Citalopram Hydrobromide
Citalopramum
Citalopramum [INN-Latin]
|
Citol
Citopam
Citox
Citrol
CPD000465669
Cytalopram
D07704
Dalsan
DB00215
EINECS 261-891-1
Elopram
HMS2090O09
HMS2093A14
Humorup
I01-0382
InChI=1/C20H21FN2O/c1-23(2)11-3-10-20(17-5-7-18(21)8-6-17)19-9-4-15(13-22)12-16(19)14-24-20/h4-9,12H,3,10-11,14H2,1-2H3
L001223
Lopac0_000258
LS-84327
Lu 10-171
Lu-10-171
MolPort-003-666-794
NCGC00015267-07
NCGC00025160-02
Nitalapram
Oropram
Pramcit
Prestwick3_000692
Recital
SAM002589960
Seropram
ST069372
STL058639
Talam
Talohexal
Temperax
UNII-0DHU5B8D6V
Vodelax
Zentius
Zetalo
|
|
| 18 |
|
Aminolevulinic acid |
Approved |
Phase 4,Phase 2 |
|
106-60-5 |
137
|
|
Synonyms:
106-60-5
35BEC718-C970-426A-9859-BF58284C60B4
5451-09-2
5-ALA
5-Amino-4-oxopentanoate
5-Amino-4-oxo-Pentanoate
5-Amino-4-oxopentanoic acid
5-Amino-4-oxo-Pentanoic acid
5-Amino-4-oxovalerate
5-Amino-4-oxovaleric acid
5-Aminolaevulinate
5-Aminolaevulinic acid
5-amino-levulinate
5-Aminolevulinate
5-Amino-Levulinate
5-Aminolevulinic acid
5-Amino-Levulinic acid
AC-054
AC1L18K9
AKOS003587520
Aladerm
Aminolevulinate
Aminolevulinic
Aminolevulinic acid
Amino-levulinic acid
BIDD:GT0260
BSPBio_003407
C00430
CCRIS 8958
CHEBI:17549
CHEMBL601
CID137
CPD000857229
D07567
dALA
DB00855
|
delta-ALA
delta-Aminolevulinate
delta-aminolevulinic acid
delta-Aminolevulinic acid
DivK1c_006954
EINECS 203-414-1
I14-10101
KBio1_001898
KBio2_002062
KBio2_004630
KBio2_007198
KBio3_002627
KBioGR_001176
KBioSS_002062
Kerastick
Levulinic acid, 5-amino- (8CI)
LMFA01100055
LS-101793
MLS001333097
MLS001333098
MolPort-001-788-423
NCGC00178086-01
Pentanoic acid, 5-amino-4-oxo- (9CI)
SAM002589919
SMR000857229
SPBio_001843
SpecPlus_000858
Spectrum_001582
Spectrum2_001662
Spectrum3_001654
Spectrum4_000618
Spectrum5_001505
ST50819610
UNII-88755TAZ87
δ-ALA
δ-aminolevulinic acid
|
|
| 19 |
|
Dabrafenib |
Approved, Investigational |
Phase 4,Phase 3,Phase 2,Phase 1 |
|
|
44462760
44516822
|
|
Synonyms:
BRAF inhibitor GSK2118436
dabrafenib
Dabrafenib
|
|
|
| 20 |
|
Edetic Acid |
Approved, Vet_approved |
Phase 4,Phase 3,Phase 2 |
|
60-00-4, 62-33-9 |
6049
|
|
Synonyms:
(ethylenedinitrilo)tetraacetic acid, ion(4−)
{[-(bis-carboxymethyl-amino)-ethyl]-carboxymethyl-amino}-acetic acid
2,2',2'',2'''-(ethane-1,2-diyldinitrilo)tetraacetate
acide edetique
Acide ethylenediaminetetracetique
Acido edetico
Acidum edeticum
CaEDTA
Calcium Disodium Edetate (JAN)
Calcium Disodium Versenate
|
Calcium disodium versenate (TN)
Edetate Calcium
Edetate calcium disodium (USP)
EDT
EDTA
EDTA, ion(4-)
Ethylenediaminetetraacetate
Ethylenediaminetetraacetic acid
N,N'-1,2-Ethane diylbis-(N-(carboxymethyl)glycine)
|
|
| 21 |
|
Bortezomib |
Approved, Investigational |
Phase 4,Phase 2,Phase 1 |
|
179324-69-7 |
387447
93860
|
|
Synonyms:
[(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid
[(1R)-3-methyl-1-[[(2S)-3-phenyl-2-(pyrazine-2-carbonylamino)propanoyl]amino]butyl]boronic acid
179324-69-7
AC1L8TUW
bortezomib
Bortezomib
Bortezomib (JAN/USAN/INN)
CHEBI:287372
CHEBI:41143
CHEMBL325041
CID387447
D03150
DB07475
DPBA
FT-0082488
I14-3268
LDP341
LDP-341
|
LPD 341
LPD-341
MLN341
MolPort-003-845-298
N-[(1R)-1-(dihydroxyboranyl)-3-methylbutyl]-Nalpha-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide
N-[(1R)-1-(DIHYDROXYBORYL)-3-methylbutyl]-N-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide
N-[(1R)-1-(DIHYDROXYBORYL)-3-METHYLBUTYL]-N-(PYRAZIN-2-YLCARBONYL)-L-PHENYLALANINAMIDE
NCI60_029010
NSC681239
NSC-681239
PROSCRIPT BORONIC ACID
PS-341
Pyz-Phe-boroLeu
S1013_Selleck
SBB071337
Velcade
Velcade (TN)
Velcade, MG-341, PS-341, Bortezomib
|
|
| 22 |
|
Dasatinib |
Approved, Investigational |
Phase 4,Phase 2,Phase 1 |
|
302962-49-8 |
3062316
|
|
Synonyms:
(18F)-N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide
1N1
2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)-N-(2-chloro-6-methylphenyl)thiazole-5-carboxamide
302962-49-8
AC1MI3ET
AC1Q2P0C
AmbotzLS-1203
anh. dasatinib
Anhydrous dasatinib
BCB03_000715
BMS 354825
BMS dasatinib
BMS354825
BMS-354825
BMS-354825, Sprycel, BMS354825, Dasatinib
C488369
CHEBI:49375
CHEMBL1421
CID3062316
D03658
dasatinib
Dasatinib
Dasatinib (anh.)
dasatinib (anhydrous)
Dasatinib (USAN)
Dasatinib [USAN]
Dasatinib anhydrous
Dasatinib, BMS 354825
dasatinibum
|
Dasatinibum
DB01254
EC-000.2122
EN002710
FT-0084503
I14-1972
Kinome_3650
LS-186641
LS-187028
LS-187773
MolPort-003-846-143
N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)thiazole-5-carboxamide
N-(2-CHLORO-6-methylphenyl)-2-({6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl}amino)-1,3-thiazole-5-carboxamide
N-(2-CHLORO-6-METHYLPHENYL)-2-({6-[4-(2-HYDROXYETHYL)PIPERAZIN-1-YL]-2-METHYLPYRIMIDIN-4-YL}AMINO)-1,3-THIAZOLE-5-CARBOXAMIDE
N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide
N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide, monohydrate
N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-1,3-thiazole-5-carboxamide
NCGC00181129-01
nchembio.117-comp11
nchembio.162-comp4
nchembio.332-comp1
NSC732517
NSC-732517
S1021_Selleck
Sprycel
SPRYCEL (TN)
Spyrcel
UNII-X78UG0A0RN
|
|
| 23 |
|
Olaparib |
Approved |
Phase 4,Phase 1 |
|
763113-22-0 |
23725625
|
|
Synonyms:
4-(3-{[4-(cyclopropylcarbonyl)piperazin-1-yl]carbonyl}-4-fluorobenzyl)phthalazin-1(2H)-one
4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one
4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one
763113-22-0
937799-91-2
Acylpiperazine analogue, 47
AKOS005145764
AZD 2281
AZD2281
AZD-2281
|
CHEMBL521686
EC-000.2324
EN002690
FT-0083489
KU-0059436
KU-59436
olaparib
Olaparib
Olaparib, KU-0059436, AZD2281, KU0059436, AZD2281
S1060_Selleck
|
|
| 24 |
|
Palbociclib |
Approved, Investigational |
Phase 4,Phase 1,Phase 2 |
|
571190-30-2 |
5330286
11431660
5005498
|
|
Synonyms:
2euf
571190-30-2
6-Acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-ylpyridin-2-ylamino)-8H-pyrido(2,3-d)pyrimidin-7-one
6-ACETYL-8-CYCLOPENTYL-5-METHYL-2-[(5-PIPERAZIN-1-YLPYRIDIN-2-YL)AMINO]PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE
6-acetyl-8-cyclopentyl-5-methyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one
6-acetyl-8-cyclopentyl-5-methyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}pyrido[2,3-d]pyrimidin-7(8H)-one
AC1NS8RV
CHEMBL189963
CID5330286
EC-000.2350
Ibrance
|
Kinome_3823
Kinome_3824
LQQ
Palbociclib
PD 0332991
PD 332991, PD 0332991, PD0332991
PD0332991
PD-0332991
PD-332991
S1116_Selleck
|
|
| 25 |
|
Ramucirumab |
Approved, Investigational |
Phase 4,Phase 2,Phase 1 |
|
947687-13-0 |
|
|
Synonyms:
|
| 26 |
|
Vorinostat |
Approved, Investigational |
Phase 4,Phase 2,Phase 1,Early Phase 1 |
|
149647-78-9 |
5311
|
|
Synonyms:
149647-78-9
1zz1
AC-1923
AC1L1K2K
BRD-K81418486-001-10-3
C111237
CCRIS 8456
CHEBI:45716
CHEMBL98
CID5311
D06320
DB02546
EC-000.2057
FT-0082592
LS-186548
LS-186997
LS-187780
m344
Merck brand of Vorinostat
MK0683
MK-0683
MLS001065855
MolPort-003-850-293
N1-hydroxy-N8-phenyloctanediamide
NCGC00168085-02
nchembio.275-comp2
nchembio.313-comp1
nchembio815-comp18
NHNPODA
N-Hydroxy-N'-phenyl octanediamide
N-hydroxy-N'-phenyl-octane-1,8-diotic acid diamide
|
N'-hydroxy-N-phenyloctanediamide
N-hydroxy-N'-phenyloctanediamide
N-Hydroxy-N'-phenyloctanediamide
N-Hyrdroxy-N'-phenyloctanediamide
NSC701852
NSC-701852
Octanedioic acid hydroxyamide phenylamide
OCTANEDIOIC ACID HYDROXYAMIDE PHENYLAMIDE
S1047_Selleck
SAHA
SAHA cpd
SAHA, Suberoylanilide hydroxamic acid
SHH
SKI390
SMR000486344
Suberanilohydroxamic acid
SuberoylaN/Aide hydroxamic acid
suberoylanilide hydroxamic acid
Suberoylanilide hydroxamic acid
SW-064652
UNII-58IFB293JI
Vorinostat
Vorinostat (JAN/USAN)
Vorinostat [USAN]
Vorinostat MSD
Vorinostatum
WIN64652
ZINC01543873
Zolinza
Zolinza (TN)
Zolinza, MK-0683, SAHA
|
|
| 27 |
|
Ceritinib |
Approved |
Phase 4,Phase 2,Early Phase 1 |
|
1032900-25-6 |
|
|
Synonyms:
2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2- isopropylsulfonyl)phenyl) pyrimidine-2,4-diamine
céritinib
LDK378
|
N-{2-[(5-chloro-2-{[2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl]amino}pyrimidin-4-yl)amino]phenyl}propane-2-sulfonamide
Zykadia
|
|
| 28 |
|
Crizotinib |
Approved |
Phase 4,Phase 2 |
|
877399-52-5 |
11626560
10366136
10366137
10366138
10366139
10366140
10366141
|
|
Synonyms:
(R)-crizotinib
crizotinib
Crizotinib
|
Crizotinibum
PF-02341066
Xalkori
|
|
| 29 |
|
Gefitinib |
Approved, Investigational |
Phase 4 |
|
184475-35-2 |
123631
|
|
Synonyms:
184475-35-2
4-(3'-chloro-4'-Fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline
4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline
6-(3-morpholinopropoxy)-N-(3-chloro-4-fluorophenyl)-7-methoxyquinazolin-4-amine
AC-1556
AC1L3X0A
AKOS000280752
BCB03_000781
Bio-0046
C419708
CCRIS 9011
CHEBI:49668
CHEMBL939
CID123631
CU-00000000396-1
D01977
DB00317
DB07998
EC-000.2409
EN002708
FT-0081035
Gefitini
gefitinib
Gefitinib
Gefitinib (JAN/USAN/INN)
Gefitinib [USAN]
Gefitinib, Iressa, ZD1839
HMS2089B19
I01-1227
IRE
|
Iressa
Iressa (TN)
Iressa(TM)
Irressat
K00240
KBioSS_002241
Kinome_3321
Kinome_3322
LS-139916
MolPort-000-883-335
N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamide
N-(3-chloro-4-Fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamine
N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine
N-(3-Chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine
N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine
N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(morpholin-4-yl)propoxy]quinazolin-4-amine
NCGC00159455-02
NCGC00159455-03
nchembio.117-comp18
nchembio866-comp14
NSC715055
S1025_Selleck
STK621310
UNII-S65743JHBS
ZD 1839
ZD1839
ZD-1839
ZD-1839, Iressa, Gefitinib
ZINC19632614
|
|
| 30 |
|
Lactitol |
Investigational |
Phase 4,Phase 1,Phase 2 |
|
585-86-4 |
3871
|
|
Synonyms:
4-O-b-D-Galactopyranosyl-D-glucitol, 9CI
E966
Emportal
Floralac
|
|
|
| 31 |
|
Lapatinib |
Approved March 2007, Investigational |
Phase 4,Phase 2 |
|
231277-92-2, 388082-78-8 |
208908
9941095
|
|
Synonyms:
1xkk
231277-92-2
388082-78-8
4-[[3-Chloro-4-(3-fluorobenzyloxy)phenyl]amino]-6-[5-[[(2-methanesulfonylethyl)amino]methyl]furan-2-yl]quinazoline
AB1004631
AC-1314
AC1L4LL4
AKOS005145766
CHEBI:49603
CHEMBL1201179
CHEMBL554
CID11557040
CID208908
D04024
D08108
DB01259
DB02584
EN002712
FMM
GSK 572016
GSK572016
GW 572016
GW 572016X
GW2016
GW-2016
GW572016
GW-572016
GW-572016F
HMS2089H10
I01-1247
Kinome_3684
|
Kinome_3685
lapatinib
Lapatinib
Lapatinib (INN)
Lapatinib [INN]
lapatinib ditosylate
Lapatinib ditosylate
Lapatinib Ditosylate
Lapatinib ditosylate (USAN)
LAPATINIB DITOSYLATE MONOHYDRATE
Lapatinib tosilate hydrate
Lapatinib tosilate hydrate (JAN)
Lapatinib, Tykerb, GW572016
LS-187029
LS-187771
N-(3-chloro-4-((3-Fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furanyl)-4-quinazolinamine
N-(3-Chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-((2-methylsulfonylethylamino)methyl)-2-furyl)quinazolin-4-amine
N-(3-Chloro-4-{[(3-fluorophenyl)methyl]oxy}phenyl)-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furanyl]-4-quinazolinamine
N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine
N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine
N-{3-CHLORO-4-[(3-FLUOROBENZYL)OXY]PHENYL}-6-[5-({[2-(METHYLSULFONYL)ETHYL]AMINO}METHYL)-2-FURYL]-4-QUINAZOLINAMINE
NCGC00167507-01
nchembio866-comp20
NSC745750
TL80090051
Tycerb
Tykerb
Tykerb (TN)
Tyverb
UNII-0VUA21238F
|
|
| 32 |
|
Antimitotic Agents |
|
Phase 4,Phase 3,Phase 2,Phase 1 |
|
|
|
| 33 |
|
Antineoplastic Agents, Phytogenic |
|
Phase 4,Phase 3,Phase 2,Phase 1 |
|
|
|
| 34 |
|
Angiogenesis Inhibitors |
|
Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 |
|
|
|
| 35 |
|
Angiogenesis Modulating Agents |
|
Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 |
|
|
|
| 36 |
|
Antibodies |
|
Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 |
|
|
|
| 37 |
|
Antibodies, Monoclonal |
|
Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 |
|
|
|
| 38 |
|
Immunoglobulins |
|
Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 |
|
|
|
| 39 |
|
Analgesics |
|
Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 |
|
|
|
| 40 |
|
Analgesics, Non-Narcotic |
|
Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 |
|
|
|
| 41 |
|
Anti-Inflammatory Agents |
|
Phase 4,Phase 2,Phase 3,Phase 1 |
|
|
|
| 42 |
|
Anti-Inflammatory Agents, Non-Steroidal |
|
Phase 4,Phase 1,Phase 2 |
|
|
|
| 43 |
|
Antirheumatic Agents |
|
Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 |
|
|
|
| 44 |
|
Gastrointestinal Agents |
|
Phase 4,Phase 3,Phase 1,Phase 2 |
|
|
|
| 45 |
|
Immunosuppressive Agents |
|
Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 |
|
|
|
| 46 |
|
Peripheral Nervous System Agents |
|
Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 |
|
|
|
| 47 |
|
Antidepressive Agents |
|
Phase 4,Phase 2,Phase 3,Phase 1 |
|
|
|
| 48 |
|
Antidepressive Agents, Second-Generation |
|
Phase 4,Phase 2,Phase 3,Phase 1 |
|
|
|
| 49 |
|
Interleukin-2 |
|
Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 |
|
|
|
| 50 |
|
Neurotransmitter Agents |
|
Phase 4,Phase 3,Phase 2,Phase 1 |
|
|
|
Interventional clinical trials:
(show top 50)
(show all 2357)
| # |
Name |
Status |
NCT ID |
Phase |
Drugs |
| 1 |
Standard Palliative Care Versus Standard Palliative Care Plus Polychemotherapy in Metastasized Malignant Melanoma |
Unknown status |
NCT00226473
|
Phase 4 |
Cisplatin, Vindesine, Dacarbazine (drugs) |
| 2 |
Intravitreal Ranibizumab for the Prevention of Radiation Maculopathy Following Plaque Radiotherapy |
Unknown status |
NCT00540930
|
Phase 4 |
Ranibizumab |
| 3 |
Long Term Results of Combined Transpupillary Thermotherapy (TTT) Indocyanine Green (ICG) Based Photodynamic Therapy (PDT) in Choroidal Melanoma |
Completed |
NCT01253759
|
Phase 4 |
|
| 4 |
Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab |
Completed |
NCT01515189
|
Phase 4 |
|
| 5 |
Can We Miss Pigmented Lesions in Psoriasis Patients? |
Completed |
NCT01053819
|
Phase 4 |
etanercept |
| 6 |
Post-Operative Drainage Following Lymph Node Dissection |
Completed |
NCT00324272
|
Phase 4 |
Fibrin Sealant (Tisseel) used in the Experimental Arm. |
| 7 |
Evaluating the Effectiveness of Escitalopram in Preventing or Reducing Depressive Symptoms in People Receiving Interleukin-2 Treatment |
Completed |
NCT00352885
|
Phase 4 |
Escitalopram;Placebo;IL-2 |
| 8 |
A Study for Lymphocele and Lymphorrhea Control Following Inguinal and Axillary Radical Lymph Node Dissection |
Completed |
NCT02476357
|
Phase 4 |
|
| 9 |
Surgery Versus Radiosurgery to Treat Metastatic Brain Tumors |
Completed |
NCT00075166
|
Phase 4 |
|
| 10 |
Effect of Topical Imiquimod on Lentigo Maligna |
Completed |
NCT01161888
|
Phase 4 |
Imiquimod |
| 11 |
Neoadjuvant Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Cutaneous Stage L-lll Melanoma |
Recruiting |
NCT02451488
|
Phase 4 |
GM-CSF |
| 12 |
Flu Vaccine Responses in the Setting of Melanoma Treatment |
Recruiting |
NCT03315975
|
Phase 4 |
|
| 13 |
Photodynamic Therapy for Lentigo Maligna Using 5-aminolevulinic Acid Nanoemulsion as a Light Sensitizing Cream |
Recruiting |
NCT02685592
|
Phase 4 |
5-aminolevulinic acid nanoemulsion |
| 14 |
Dabrafenib and/or Trametinib Rollover Study |
Recruiting |
NCT03340506
|
Phase 4 |
dabrafenib;trametinib |
| 15 |
Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study. |
Recruiting |
NCT01794793
|
Phase 4 |
Pasireotide |
| 16 |
Immune Modulation Study in Patients With Metastatic Melanoma Treated With Anti-PD1 Monoclonal Antibodies |
Active, not recruiting |
NCT02626065
|
Phase 4 |
Nivolumab |
| 17 |
TTT Versus TTT and Triamcinolone to Decrease Exudation in Choroidal Melanoma After Proton Beam Therapy |
Active, not recruiting |
NCT02379000
|
Phase 4 |
Triamcinolone Acetonide |
| 18 |
An Open-Label Study of Zelboraf (Vemurafenib) in Patients With Braf V600 Mutation Positive Metastatic Melanoma |
Active, not recruiting |
NCT01898585
|
Phase 4 |
Zelboraf |
| 19 |
A National Phase IV Study With Ipilimumab for Patients With Advanced Malignant Melanoma. |
Active, not recruiting |
NCT02068196
|
Phase 4 |
Ipilimumab |
| 20 |
Sentinel Lymph Node Biopsy Findings in Patients With Breast Cancer |
Active, not recruiting |
NCT02287675
|
Phase 4 |
Lymphoseek;Sulfur Colloid |
| 21 |
Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma |
Not yet recruiting |
NCT02645149
|
Phase 4 |
Standard therapy or clinical trial;Matched targeted therapy;Trametinib and / or supportive care |
| 22 |
Evolution of the Heart Function When Monitoring Immunotherapies Anti-cancerous Inhibiting PD-1 |
Not yet recruiting |
NCT03313544
|
Phase 4 |
Nivolumab |
| 23 |
HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma |
Terminated |
NCT01683188
|
Phase 4 |
vemurafenib + HD IL-2 |
| 24 |
HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma |
Terminated |
NCT01856023
|
Phase 4 |
High Dose Interleukin-2;Ipilimumab |
| 25 |
Assessment and Tracking of Long-term Alefacept Safety |
Terminated |
NCT00454701
|
Phase 4 |
Alefacept exposure |
| 26 |
Genetically-informed Therapies for Patients With Metastatic Cancer |
Withdrawn |
NCT02000739
|
Phase 4 |
|
| 27 |
Modified Melanoma Vaccine for High Risk or Low Residual Disease Patients |
Unknown status |
NCT01861938
|
Phase 2, Phase 3 |
|
| 28 |
A Phase 3 Study to Compare Efficacy and Safety of Masitinib to Dacarbazine in the Treatment of Patients With Non-Resectable or Metastatic Stage 3 or Stage 4 Melanoma Carrying a Mutation in the Juxta Membrane Domain of C-Kit |
Unknown status |
NCT01280565
|
Phase 3 |
masitinib;Dacarbazine |
| 29 |
Interferon Alfa With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma |
Unknown status |
NCT00002767
|
Phase 3 |
|
| 30 |
High-Dose or Low-Dose Interferon Alfa Compared With No Further Therapy Following Surgery in Treating Patients With Stage III Melanoma |
Unknown status |
NCT00002763
|
Phase 3 |
|
| 31 |
Interferon Alfa Following Surgery in Treating Patients With Stage III Melanoma |
Unknown status |
NCT00006249
|
Phase 3 |
|
| 32 |
Vaccine Therapy in Treating Patients With Primary Stage II Melanoma |
Unknown status |
NCT00005052
|
Phase 3 |
|
| 33 |
Interleukin-2 With or Without Histamine Dihydrochloride in Treating Patients With Stage IV Melanoma Metastatic to the Liver |
Unknown status |
NCT00039234
|
Phase 3 |
histamine dihydrochloride |
| 34 |
Vaccine Therapy for Patients With Stage III Melanoma |
Unknown status |
NCT00052130
|
Phase 3 |
|
| 35 |
Vaccine Therapy for Patients With Stage IV Melanoma |
Unknown status |
NCT00052156
|
Phase 3 |
|
| 36 |
Treatment Of Radiation Retinopathy Trial |
Unknown status |
NCT00811200
|
Phase 2, Phase 3 |
ranibizumab;triamcinolone acetonide |
| 37 |
Immunotherapy After Surgery in Treating Patients With Breast Cancer, Colon Cancer, or Melanoma |
Unknown status |
NCT00002455
|
Phase 3 |
|
| 38 |
Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC |
Unknown status |
NCT00779714
|
Phase 3 |
DTIC (dacarbazine);paclitaxel + cisplatin;treosulfan + cytarabine |
| 39 |
Collaborative Ocular Melanoma Study (COMS) |
Unknown status |
NCT00000124
|
Phase 3 |
|
| 40 |
Standard High-Dose Alpha Interferon Versus Intermittent High-Dose Alpha Interferon |
Unknown status |
NCT00226408
|
Phase 3 |
Interferon-alpha-2b |
| 41 |
Treatment of Port Wine Stains in Children With Pulsed Dye Laser and Timolol Gel |
Unknown status |
NCT01272609
|
Phase 3 |
Timolol + LCP |
| 42 |
18F-fluorodeoxyglucose (18F-FDG) Positron Emission Tomography in Oncology |
Unknown status |
NCT00207298
|
Phase 3 |
|
| 43 |
MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma |
Completed |
NCT00094653
|
Phase 3 |
MDX-010 (anti-CTLA4) monoclonal antibody |
| 44 |
Interferon Alfa With or Without Combination Chemotherapy Plus Interleukin-2 in Treating Patients With Melanoma |
Completed |
NCT00002882
|
Phase 3 |
Cisplatin;Dacarbazine;Vinblastine |
| 45 |
Nordic Adjuvant IFN Melanoma Trial |
Completed |
NCT01259934
|
Phase 3 |
Interferon-alpha2b - 1 year;Interferon-alpha2b - 2 years |
| 46 |
Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT) |
Completed |
NCT01974752
|
Phase 3 |
75mg selumetinib;placebo;Dacarbazine |
| 47 |
Temozolomide Versus Dacarbazine in Stage IV Metastatic Melanoma (Study P03267) |
Completed |
NCT00091572
|
Phase 3 |
Temozolomide;Dacarbazine |
| 48 |
Dacarbazine and/or Cisplatin Compared With Complete Metastasectomy in Treating Patients With Stage IV Melanoma |
Completed |
NCT00072124
|
Phase 3 |
cisplatin;dacarbazine |
| 49 |
GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma |
Completed |
NCT01245062
|
Phase 3 |
GSK1120212;Chemotherapy |
| 50 |
Lucentis as an Adjuvant Therapy With TTT-ICG Based in Choroidal Melanoma |
Completed |
NCT00680225
|
Phase 3 |
Ranibizumab injection and TTT - ICG based |
Inferred drug relations via
UMLS
69
/
NDF-RT
47
:
Cochrane evidence based reviews: melanoma
|
